Pietras RJ - Search Results

1

EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer.

Chan AM, Aguirre B, Liu L, Mah V, Balko JM, Tsui J, Wadehra NP, Moatamed NA, Khoshchehreh M, Dillard CM, Kiyohara M, Elshimali Y, Chang HR, Marquez-Garban D, Hamilton N, Pietras RJ, Gordon LK, Wadehra M. Chan AM, et al. Among authors: pietras rj. Cancers (Basel). 2024 Apr 12;16(8):1481. doi: 10.3390/cancers16081481. Cancers (Basel). 2024. PMID: 38672563 Free PMC article.

2

Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer.

Hamilton N, Márquez-Garbán D, Mah V, Fernando G, Elshimali Y, Garbán H, Elashoff D, Vadgama J, Goodglick L, Pietras R. Hamilton N, et al. Biomed Res Int. 2015;2015:925703. doi: 10.1155/2015/925703. Epub 2015 Mar 22. Biomed Res Int. 2015. PMID: 25874233 Free PMC article.

3

Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.

Hamilton N, Marquez-Garban D, Mah VH, Elshimali Y, Elashoff D, Garon EB, Vadgama J, Pietras R. Hamilton N, et al. Crit Rev Oncog. 2015;20(5-6):373-90. doi: 10.1615/CritRevOncog.v20.i5-6.100. Crit Rev Oncog. 2015. PMID: 27279236 Free PMC article. Review.

4

Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.

Hamilton N, Austin D, Márquez-Garbán D, Sanchez R, Chau B, Foos K, Wu Y, Vadgama J, Pietras R. Hamilton N, et al. Int J Mol Sci. 2017 Nov 2;18(11):2305. doi: 10.3390/ijms18112305. Int J Mol Sci. 2017. PMID: 29099049 Free PMC article.

5

Estrogen receptor-beta is a potential target for triple negative breast cancer treatment.

Austin D, Hamilton N, Elshimali Y, Pietras R, Wu Y, Vadgama J. Austin D, et al. Oncotarget. 2018 Sep 21;9(74):33912-33930. doi: 10.18632/oncotarget.26089. eCollection 2018 Sep 21. Oncotarget. 2018. PMID: 30338035 Free PMC article.

6

New approaches to reverse resistance to hormonal therapy in human breast cancer.

Weinberg OK, Marquez-Garban DC, Pietras RJ. Weinberg OK, et al. Among authors: pietras rj. Drug Resist Updat. 2005 Aug;8(4):219-33. doi: 10.1016/j.drup.2005.06.002. Epub 2005 Jul 27. Drug Resist Updat. 2005. PMID: 16054421 Review.

7

CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer.

Deng X, Apple S, Zhao H, Song J, Lee M, Luo W, Wu X, Chung D, Pietras RJ, Chang HR. Deng X, et al. Among authors: pietras rj. Oncotarget. 2017 Jun 13;8(24):38294-38308. doi: 10.18632/oncotarget.16203. Oncotarget. 2017. PMID: 28418843 Free PMC article.

8

Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.

Márquez-Garbán DC, Deng G, Comin-Anduix B, Garcia AJ, Xing Y, Chen HW, Cheung-Lau G, Hamilton N, Jung ME, Pietras RJ. Márquez-Garbán DC, et al. Among authors: pietras rj. J Steroid Biochem Mol Biol. 2019 Oct;193:105415. doi: 10.1016/j.jsbmb.2019.105415. Epub 2019 Jun 19. J Steroid Biochem Mol Biol. 2019. PMID: 31226312 Free PMC article.

9

Membrane-associated estrogen receptor signaling pathways in human cancers.

Pietras RJ, Márquez-Garbán DC. Pietras RJ, et al. Clin Cancer Res. 2007 Aug 15;13(16):4672-6. doi: 10.1158/1078-0432.CCR-07-1373. Clin Cancer Res. 2007. PMID: 17699844 Review. No abstract available.

10

Estrogen-signaling pathways in lung cancer.

Márquez-Garbán DC, Pietras RJ. Márquez-Garbán DC, et al. Among authors: pietras rj. Adv Exp Med Biol. 2008;617:281-9. doi: 10.1007/978-0-387-69080-3_26. Adv Exp Med Biol. 2008. PMID: 18497051 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

132 results

Search Page